Published in P T on November 01, 2013
Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? J Neuroinflammation (2014) 1.41
Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report. Case Rep Hematol (2014) 0.75
Recombinant factor VIIa use in patients presenting with intracranial hemorrhage. Springerplus (2014) 0.75
Safety and Effectiveness of Factor VIII Inhibitor Bypassing Activity (FEIBA) and Fresh Frozen Plasma in Oral Anticoagulant-Associated Intracranial Hemorrhage: A Retrospective Analysis. Neurocrit Care (2017) 0.75
Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med (2010) 6.81
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA (2006) 3.41
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med (2002) 2.85
Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med (2011) 2.68
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost (2012) 2.61
Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost (2006) 1.95
Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res (2005) 1.91
Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol (2002) 1.71
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost (2013) 1.70
Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate. Ann Emerg Med (2009) 1.58
Thrombogenicity of prothrombin complex concentrates. Thromb Res (1999) 1.09
Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med (2003) 1.07
Transfusion-Related Acute Lung Injury: Incidence, Pathogenesis and the Role of Multicomponent Apheresis in Its Prevention. Transfus Med Hemother (2008) 1.05
Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. Ann Hematol (2009) 1.02
Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost (1998) 1.01
FEIBA: mode of action. Haemophilia (2004) 0.96
Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia (2007) 0.94
Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res (2008) 0.90
Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate. Thromb Res (2008) 0.89
Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res (1999) 0.86
Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med (2000) 0.85
Perioperative myocardial infarction in a patient receiving low-dose prothrombin complex concentrates. Thromb Haemost (2007) 0.85
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med (2009) 0.84
Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA. Blood Coagul Fibrinolysis (2002) 0.84
Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol (1995) 0.78
Assessment of hospital pharmacy preparedness for mass casualty events. P T (2015) 0.75
Frequency of and reasons for pharmacy residents breaching the National Matching Services applicant agreement. Am J Health Syst Pharm (2010) 0.75